loading
Skye Bioscience Inc stock is traded at $1.87, with a volume of 220.56K. It is down -6.97% in the last 24 hours and up +18.35% over the past month. Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$2.01
Open:
$2.01
24h Volume:
220.56K
Relative Volume:
0.34
Market Cap:
$57.93M
Revenue:
-
Net Income/Loss:
$-21.24M
P/E Ratio:
-2.2318
EPS:
-0.8379
Net Cash Flow:
$-22.47M
1W Performance:
+3.31%
1M Performance:
+18.35%
6M Performance:
-62.22%
1Y Performance:
-84.73%
1-Day Range:
Value
$1.78
$2.03
1-Week Range:
Value
$1.78
$2.0998
52-Week Range:
Value
$1.14
$12.77

Skye Bioscience Inc Stock (SKYE) Company Profile

Name
Name
Skye Bioscience Inc
Name
Phone
(858) 410-0266
Name
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Name
Employee
16
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
SKYE's Discussions on Twitter

Compare SKYE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
 icon
SKYE
Skye Bioscience Inc.
3.10 12.89M 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
20.79 372.90M 0 0 0 0.00
 icon
JUNE
Dhandho Junoon Etf
11.00 215.29M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
2.87 149.00M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1641 340.19M 2.07B -1.42B -1.37B -0.6765
 icon
MOBBW
Mobilicom Limited Warrants
0.3476 371.47M 0 0 0 0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-28-25 Initiated William Blair Outperform
Sep-30-24 Initiated Scotiabank Sector Outperform
Sep-10-24 Initiated JMP Securities Mkt Outperform
Jul-09-24 Initiated Craig Hallum Buy
May-23-24 Initiated Cantor Fitzgerald Overweight
Apr-12-24 Initiated Oppenheimer Outperform
View All

Skye Bioscience Inc Stock (SKYE) Latest News

pulisher
May 16, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

May 16, 2025
pulisher
May 15, 2025

Skye Bioscience (NASDAQ:SKYE) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat

May 15, 2025
pulisher
May 14, 2025

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 14, 2025
pulisher
May 14, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Consensus PT from Analysts - Defense World

May 14, 2025
pulisher
May 14, 2025

Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $16.60 - Defense World

May 14, 2025
pulisher
May 13, 2025

Skye Bioscience Awards 100,000 Share Options at $1.82 with 4-Year Vesting Terms - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Skye Bioscience (SKYE) Reveals Key Findings on CB1 Inhibitors an - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Skye Bioscience Clinical Model Demonstrating Necessity of - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Bought by Barclays PLC - Defense World

May 13, 2025
pulisher
May 13, 2025

Barclays PLC Has $198,000 Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

May 13, 2025
pulisher
May 12, 2025

Skye Bioscience (SKYE) Receives Adjusted Price Target from Oppen - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Oppenheimer cuts Skye Bioscience price target to $17 By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

Oppenheimer cuts Skye Bioscience price target to $17 - Investing.com

May 12, 2025
pulisher
May 12, 2025

Braidwell LP Invests $2.34 Million in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat

May 12, 2025
pulisher
May 10, 2025

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire

May 10, 2025
pulisher
May 09, 2025

Earnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D Expansion - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Skye Bioscience, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SKYE) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Pro - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Schonfeld Strategic Advisors LLC Purchases 463,644 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat

May 09, 2025
pulisher
May 09, 2025

Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and Financial Stability Amid Regulatory Challenges - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Skye Bioscience Q1 2025: Progress in Obesity Treatment - TipRanks

May 09, 2025
pulisher
May 08, 2025

SKYE Advances Nimacimab as Promising Obesity Treatment | SKYE Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 - GlobeNewswire

May 07, 2025
pulisher
May 01, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Holdings Increased by Geode Capital Management LLC - Defense World

May 01, 2025
pulisher
May 01, 2025

Geode Capital Management LLC Has $1.15 Million Stake in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

May 01, 2025
pulisher
Apr 29, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Clinical-Stage Biotech Skye Sets Triple Conference Schedule: Key Obesity Drug Updates Coming in May - Stock Titan

Apr 29, 2025
pulisher
Apr 27, 2025

Skye Bioscience (SKYE) Grants Stock Options to New Employee | SK - GuruFocus

Apr 27, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Skye Bioscience Board Approves 19,000 Share Options Grant Under 2024 Inducement Plan - Stock Titan

Apr 25, 2025
pulisher
Apr 25, 2025

Skye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive Plan - Nasdaq

Apr 25, 2025
pulisher
Apr 23, 2025

Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com

Apr 23, 2025
pulisher
Apr 22, 2025

SIMPLY BETTER BRANDS ANNOUNCES RESULTS FOR FISCAL 2024, HIGHLIGHTING 77% INCREASE IN TRUBAR™ REVENUE, AND CORPORATE NAME CHANGE TO TRUBAR INC. - The Globe and Mail

Apr 22, 2025
pulisher
Apr 22, 2025

William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat

Apr 22, 2025
pulisher
Apr 22, 2025

(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com

Apr 22, 2025
pulisher
Apr 21, 2025

SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com

Apr 21, 2025
pulisher
Apr 19, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

William Blair Predicts Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025

Skye Bioscience Inc Stock (SKYE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Skye Bioscience Inc Stock (SKYE) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Diep Tuan Tu
Chief Development Officer
Nov 15 '24
Sale
5.55
85
472
101,748
ARSENAULT KAITLYN
Chief Financial Officer
Nov 18 '24
Sale
4.99
43,206
215,598
166,342
ARSENAULT KAITLYN
Chief Financial Officer
Nov 15 '24
Sale
5.55
190
1,054
209,548
DHILLON PUNIT
Chief Executive Officer
Nov 18 '24
Sale
4.99
82,546
411,905
329,823
DHILLON PUNIT
Chief Executive Officer
Nov 15 '24
Sale
5.55
364
2,020
412,369
Grayson Paul A.
Director
Nov 18 '24
Sale
4.99
86,244
430,358
259,701
Grayson Paul A.
Director
Nov 15 '24
Sale
5.55
307
1,704
345,945
$1.28
price down icon 1.54%
$30.93
price up icon 7.58%
$565.63
price up icon 0.69%
$3.99
price up icon 5.28%
$285.31
price up icon 0.67%
$71.31
price up icon 2.56%
Cap:     |  Volume (24h):